Researchers have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO. Their study shows that blocking MARCO in ...
Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called ...
1 天
News-Medical.Net on MSNTargeting MARCO enhances cancer immunotherapy effectivenessResearchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO.
Macbecin II was identified as a compound that upregulates MHC-I expression, enhancing immune-mediated cancer cell killing. In ...
Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO. Their study, published ...
Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with ...
Analysis: Gut microbiota-derived hexa-acylated lipopolysaccharides enhance cancer immunotherapy responses ... that PMB-treated mice exhibited reduced infiltration of interferon-gamma (IFN-γ ...
Immunotherapy has revolutionized the management of cancer, including liver malignancies ... This effect is associated with increased infiltration and activation of cytotoxic T lymphocytes and ...
He was enrolled in a clinical trial for immunotherapy — a type of treatment that uses the patient's own immune system to fight cancer — that began in October 2013. Lung cancer poses a larger ...
Driving Innovation of Cancer Immunotherapy BOT has demonstrated ... enhancing T-cell infiltration and antitumor responses in preclinical models. These findings provide a strong rationale for ...
7 天
GlobalData on MSNImmunoGenesis doses first subject in Phase I/II trial of hypoxia reversal agentImmunoGenesis has initiated the first subject dosing in a multicentre Phase I/II trial of IMGS-101 (evofosfamide), the ...
ImmunoGenesis doses 1st patient in phase 1/2 trial of IMGS-101 in combo with balstilimab & zalifrelimab to treat immune-excluded tumours: Houston Saturday, March 8, 2025, 18:00 Hr ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果